Physician profile
Mark A Tulli
NPI 1265484257
$10,385.51
in general payments reported to CMS, 2019-2025
31 companies · $808 in 2025
The $808 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,092 · 2020: $2,077 · 2021: $1,217 · 2022: $837 · 2023: $1,152 · 2024: $1,202 · 2025: $808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,162.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,668.95 | 2019-2025 | Navitor |
| Abiomed | $1,023.55 | 2019-2025 | Impella |
| Medtronic, INC. | $954.48 | 2022-2024 | Corevalve Evolut R, Ffrangio, Onyx Frontier |
| Amgen INC. | $937.07 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $657.11 | 2019-2025 | Avvigo Guidance System, General - Balloon Catheters, Varithena Administration Pack |
| Medtronic Vascular, INC. | $472.42 | 2019 | |
| Edwards Lifesciences Corporation | $414.63 | 2019-2023 | Sapien 3 Ultra Resilia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $302.12 | 2019-2025 | Jardiance |
| Acist Medical Systems, INC. | $225.99 | 2019-2024 | |
| Lexicon Pharmaceuticals, INC. | $177.37 | 2023-2024 | Inpefa |
| Novartis Pharmaceuticals Corporation | $159.08 | 2019-2025 | |
| Shockwave Medical, INC | $148.97 | 2021 | |
| Penumbra, INC. | $146.42 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $143.21 | 2019-2024 | Xarelto |
| Stryker Corporation | $133.90 | 2025 | Limflow System |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $129.33 | 2022-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $121.76 | 2022-2025 | Verquvo |
| Recor Medical INC | $112.05 | 2024 | Paradise Renal Denervation System |
| Astrazeneca Pharmaceuticals LP | $77.57 | 2019-2025 | Bevespi Aerosphere |
| Pfizer INC. | $65.08 | 2020-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $53.27 | 2024 | Arcalyst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $46.90 | 2019-2023 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $40.04 | 2023-2025 | |
| Silk Road Medical, INC. | $36.41 | 2023-2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Angiodynamics, INC. | $31.54 | 2025 | Auryon Laser System 100-120 Vac |
| Cardiva Medical, INC. | $25.98 | 2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| Organogenesis INC. | $25.72 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $15.41 | 2023 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $14.72 | 2019 | |
| Cook Medical LLC | $14.46 | 2020 | |
| Bardy Diagnostics, INC. | $10.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Tulli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.